Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:59 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 234 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Staphylococcus Aureus Clear all
Completed Phase 1Phase 2 Interventional Results available

Study Evaluating Safety, Tolerability, and Efficacy of Intravenous AP-SA02 in Subjects With S. Aureus Bacteremia

NCT05184764
View directory record Official record
Conditions
Bacteremia, Staphylococcus Aureus, Staphylococcus Aureus Bacteremia, Bacteremia Staph, Bacteremia Due to Staphylococcus Aureus
Interventions
AP-SA02, Placebo
Biological · Other
Lead sponsor
Armata Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
23
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Cephalexin Versus Clindamycin for Suspected CA-MRSA Skin Infections

NCT00352612
View directory record Official record
Conditions
Staphylococcal Infection, Abscess, Staphylococcal Skin Infection, Folliculitis
Interventions
clindamycin, cephalexin
Drug
Lead sponsor
Aaron Chen
Other
Eligibility
6 Months to 18 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 13, 2013 · Synced Oct 20, 2026, 4:59 PM EDT
Terminated No phase listed Observational

Host Factors in Invasive and Recurrent Staphylococcus Aureus Infection

NCT00911430
View directory record Official record
Conditions
Staphylococcal Aureus Infection, Recurrent Staphylococcal Infection, Invasive Staphylococcal Infection
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 20, 2026, 4:59 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

S. Aureus Translocation From Skin and Nose to Periprosthetic Tissues

NCT04666532
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 14, 2020 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Methicillin-resistant Staphylococcus Aureus (MRSA) Skin and Soft Tissue Infection (SSTI) Prevention in Military Trainees

NCT01105767
View directory record Official record
Conditions
Staphylococcus Aureus, MRSA Skin Infections, Staphylococcal Skin Infections
Interventions
Chlorhexidine gluconate, Supplemental training, education and hygiene
Drug · Other
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 42 Years · Male only
Enrollment
30,209 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 3, 2023 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Study of the Efficacy and Safety of MEDI4893

NCT02296320
View directory record Official record
Conditions
Staphylococcus Aureus Pneumonia
Interventions
MEDI4893, Placebo
Drug · Other
Lead sponsor
MedImmune LLC
Industry
Eligibility
18 Years to 130 Years
Enrollment
213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Atlanta, Georgia • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 23, 2019 · Synced Oct 20, 2026, 4:59 PM EDT
Completed No phase listed Observational

Risk Factors for Linezolid Resistance in Staphylococcus Aureus

NCT00519025
View directory record Official record
Conditions
Linezolid Resistance, Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
360 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 12, 2018 · Synced Oct 20, 2026, 4:59 PM EDT
No Longer Available No phase listed Expanded access Accepts healthy volunteers

Direct Antibiotic Delivery of Cefazolin Into Soft Tissue Infections Using Subcutaneous Injection and Ultrasonic Dispersion

NCT01238276
View directory record Official record
Conditions
Infection, Soft Tissue, Infection, Wound, Cellulitis, Diabetic Foot Ulcer
Interventions
Cefazolin, Silberg Tissue Preparation System
Drug · Device
Lead sponsor
Sonescence, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Sebastopol, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Retapamulin as a Decolonizing Agent for MRSA

NCT03304873
View directory record Official record
Conditions
MRSA
Interventions
Retapamulin, Placebo Ointment
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
9 Months to 17 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 19, 2020 · Synced Oct 20, 2026, 4:59 PM EDT
Withdrawn Phase 4 Interventional

Epidemiology and Treatment of Small-colony Variant Staphylococcus Aureus in Cystic Fibrosis

NCT02547116
View directory record Official record
Conditions
Cystic Fibrosis, MRSA
Interventions
Rifampin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 14, 2021 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Phase 2a Study of CG400549 for the Treatment of cABSSSI Caused by Methicillin-resistant Staphylococcus Aureus

NCT01593761
View directory record Official record
Conditions
Skin Infection
Interventions
CG400549
Drug
Lead sponsor
CrystalGenomics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
La Mesa, California
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 20, 2026, 4:59 PM EDT
Completed No phase listed Observational

MicroPhage S. Aureus / MSSA / MRSA Blood Culture Beta Trial

NCT00814151
View directory record Official record
Conditions
Bacteremia, Staphylococcal Infection, Sepsis, Infection
Interventions
MicroPhage S. aureus / MSSA / MRSA Blood Culture Test (prototype)
Other
Lead sponsor
MicroPhage, Inc.
Industry
Eligibility
18 Years and older
Enrollment
712 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Evanston, Illinois • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 24, 2008 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Safety and Efficacy of Telavancin in the Treatment of Gram Positive Bloodstream Infections in Cancer Patients

NCT01321879
View directory record Official record
Conditions
Infection, Bacteremia
Interventions
Telavancin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 27, 2019 · Synced Oct 20, 2026, 4:59 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Effectiveness of Highly Purified Anhydrous (HPA) Lanolin Versus Extra-Virgin Coconut Oil in Preventing Subacute Lactation Mastitis

NCT06317688
View directory record Official record
Conditions
Lactation Mastitis, Breast Feeding, Staphylococcus Aureus Infection
Interventions
Extra-Virgin Coconut Oil
Dietary Supplement
Lead sponsor
Texas Woman's University
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2024 · Synced Oct 20, 2026, 4:59 PM EDT
Terminated No phase listed Observational

Evaluation of Vancomycin Treatment of Infections Due to Staphylococcus Aureus

NCT00862862
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus

NCT00107952
View directory record Official record
Conditions
Bacterial Pneumonia
Interventions
Telavancin, Vancomycin
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
761 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
Springfield, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2019 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Mupirocin in Eradicating Colonization With S. Aureus in Critically Ill Infants

NCT01827358
View directory record Official record
Conditions
Staphylococcal Infection
Interventions
Mupirocin calcium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 24 Months
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Atlanta, Georgia • Baltimore, Maryland • Kansas City, Missouri + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 7, 2017 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Staphylococcus Aureus Toxoids Phase 1-2 Vaccine Trial

NCT01011335
View directory record Official record
Conditions
Staphylococcus Aureus
Interventions
Monovalent rAT, Monovalent rLukS-PV, Bivalent rLukS-PV / rAT, Placebo with adjuvant, Placebo
Biological
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 55 Years
Enrollment
176 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
2
States / cities
Fort Sam Houston, Texas • Portsmouth, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 20, 2026, 4:59 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

New Mexico Honey Wound Treatment Research Study

NCT01748318
View directory record Official record
Conditions
Community-acquired Methicillin-resistant Staphylococcus Aureus Infection
Interventions
New Mexico Honey, Bactrim DS
Drug
Lead sponsor
R. Stephen Rankin, M.D.
Individual
Eligibility
16 Years to 75 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Farmington, New Mexico
Source: ClinicalTrials.gov public record
Updated May 10, 2016 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Altabax Ointment in the Treatment of Secondarily Infected Atopic Dermatitis

NCT01064947
View directory record Official record
Conditions
Atopic Dermatitis, Secondary Infection
Interventions
Retapamulin 1%
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
2 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Sep 22, 2016 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Not applicable Interventional Results available

Project CLEAR - Changing Lives by Eradicating Antibiotic Resistance

NCT01209234
View directory record Official record
Conditions
Methicillin-resistant Staphylococcus Aureus
Interventions
Standard-of-Care Education, MRSA Decolonization
Behavioral · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
2,140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
24
States / cities
Aliso Viejo, California • Anaheim, California • Downey, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2025 · Synced Oct 20, 2026, 4:59 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Impact of Germicidal Light

NCT03886337
View directory record Official record
Conditions
Bacterial Transmission, S.Aureus Transmission, Operating Room Exposure to S. Aureus, 90-day Postoperative Surgical Site Infections, Superficial and Deep
Interventions
Germicidal lighting
Device
Lead sponsor
University of Iowa
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 5, 2020 · Synced Oct 20, 2026, 4:59 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Evaluation of 3 Versus 10 Days of Antibiotics in Skin Abscesses After Surgical Drainage

NCT02024867
View directory record Official record
Conditions
Skin Disease, Bacterial, Abscess
Interventions
Trimethoprim-Sulfamethoxazole
Drug
Lead sponsor
Lucy Holmes, MD
Other
Eligibility
3 Months to 17 Years
Enrollment
249 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2015 · Synced Oct 20, 2026, 4:59 PM EDT
Completed No phase listed Observational

Initial and Chronic Methicillin Resistant Staphylococcus Aureus (MRSA) Infection in Cystic Fibrosis (CF)

NCT02684422
View directory record Official record
Conditions
Methicillin-Resistant Staphylococcus Aureus, Cystic Fibrosis
Interventions
Intervention N/A. Observational study
Other
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
4 Years to 99 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
3
States / cities
Birmingham, Alabama • Chapel Hill, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Oct 20, 2026, 4:59 PM EDT